Pàgina inicial > Resultats de la cerca: Antivirals
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 11 registres trobats en 0.02 segons.
Articles, 8 registres trobats
Documents de recerca, 3 registres trobats
Articles 8 registres trobats  
1.
12 p, 1.8 MB Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen / Rodon, Jordi (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Muñoz-Basagoiti, Jordana (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Perez-Zsolt, Daniel (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Noguera-Julian, Marc (Universitat de Vic - Universitat Central de Catalunya) ; Paredes, Roger (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mateu, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Quiñones, Carles (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Perez, Carles (Barcelona Supercomputing Center) ; Erkizia, Itziar (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Blanco Guillermo, Ignacio (Institut Germans Trias i Pujol) ; Valencia, Alfonso (Institució Catalana de Recerca i Estudis Avançats) ; Guallar, Victor (Institució Catalana de Recerca i Estudis Avançats) ; Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Blanco, Julià (Institut Germans Trias i Pujol) ; Segalés, Joaquim (Departament de Sanitat i Anatomia Animals, Facultat de Veterinària) ; Clotet Sala, Bonaventura (Institut Germans Trias i Pujol) ; Vergara-Alert, Júlia (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Izquierdo Useros, Nuria (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
There is an urgent need to identify therapeutics for the treatment of Coronavirus disease 2019 (COVID-19). Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. [...]
2021 - 10.3389/fphar.2021.64667
Frontiers in Pharmacology, Vol. 12 (march 2021)  
Registre complet - Creative Commons
2.
8 p, 722.5 KB The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease / Young, Jim (University Hospital Basel (Basilea, Suïssa)) ; Weis, Nina (Copenhagen University Hospital) ; Hofer, Harald (Medical University of Vienna) ; Irving, William (University of Nottingham) ; Weiland, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Giostra, Emiliano (Hôpitaux universitaires de Genève) ; Pascasio, Juan Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Castells, Lluís (Hospital Universitari Vall d'Hebron) ; Prieto, Martin (Hospital Universitari i Politècnic La Fe (València)) ; Postema, Roelien (Bristol-Myers Squibb) ; Lefevre, Cinira (Bristol-Myers Squibb) ; Evans, David (Bristol-Myers Squibb) ; Bucher, Heiner (University Hospital Basel (Basilea, Suïssa)) ; Calleja, Jose Luis (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Universitat Autònoma de Barcelona
There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options. [...]
2017 - 10.1186/s12879-016-2106-x
BMC Infectious diseases, Vol. 17 (january 2017)  
Registre complet - Creative Commons
3.
6 p, 232.0 KB Clinical Trials of Repurposed Antivirals for SARS-CoV-2 / Martinez, Miguel Angel (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). [...]
2020 - 10.1128/AAC.01101-20
Antimicrobial Agents and Chemotherapy, Vol. 64 (august 2020)  
Registre complet -
4.
8 p, 251.6 KB Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B / Buti, Maria (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Stepanova, Maria (Center for Outcomes Research in Liver Disease, Washington, DC, USA) ; Palom, Adriana (Hospital Universitari Vall d'Hebron) ; Riveiro Barciela, Mar (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Nader, Fatema (Center for Outcomes Research in Liver Disease, Washington) ; Roade, Luisa (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Esteban, Rafael (Esteban Mur) (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Younossi, Zobair (Betty and Guy Beatty Center for Integrated Research) ; Universitat Autònoma de Barcelona
Health-related quality of life (HRQoL) determined by patient-reported outcomes (PROs) is impaired in chronic hepatitis B (CHB) and C patients, but there are no data regarding patients with chronic hepatitis D (CHD). [...]
2021 - 10.1016/j.jhepr.2021.100280
JHEP Reports, Vol. 3 (march 2021)  
Registre complet - Creative Commons
5.
5 p, 96.2 KB Incidence of depression in patients with hepatitis C treated with direct-acting antivirals / Egmond, Elfi (Universitat Autònoma de Barcelona. Departament de Psicologia Clínica i de la Salut) ; Mariño, Zoe (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Navinés, Ricard (Universitat de Barcelona. Institut de Neurociències) ; Oriolo, Giovanni (Universitat de Barcelona. Institut de Neurociències) ; Pla, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bartres, Concepció (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Lens, Sabela (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Forns, Xavier (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Martin-Santos, Rocio (Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ribeirão Preto, Brazil)
Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i. e. , interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. [...]
2019 - 10.1590/1516-4446-2018-0336
Brazilian Journal of Psychiatry, Vol. 42 (july 2019) , p. 72-76  
Registre complet - Creative Commons
6.
9 p, 1.3 MB Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype / von Massow, Georg (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Cehic, D. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Gregori i Font, Josep (Roche Diagnostics S.L) ; Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Macià, María Dolores (Institut d'Investigació Sanitària Illes Balears) ; Escarda, Ana (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Esteban Mur, Juan Ignacio (Universitat Autònoma de Barcelona. Departament de Medicina) ; Quer, Josep 1963- (Universitat Autònoma de Barcelona. Departament de Medicina)
Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. [...]
2019 - 10.2147/IDR.S195441
Infection and drug resistance, Vol. 12 (2019) , p. 947-955  
Registre complet - Creative Commons
7.
17.3 KB Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections : A real-life experience / del Campo, José A. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Parra-Sánchez, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Figueruela, Blanca (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; García-Rey, Silvia (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Quer, Josep 1963- (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Gregori i Font, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bernal, Samuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Grande, Lourdes (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Palomares, José C. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Romero-Gómez, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Universitat Autònoma de Barcelona
The effectiveness of the new generation of hepatitis C treatments named direct-acting antiviral agents (DAAs) depends on the genotype, subtype, and resistance-associated substitutions present in individual patients. [...]
2018 - 10.1016/j.ijid.2017.12.016
International journal of infectious diseases, Vol. 67 (february 2018) , p. 114-117  
Registre complet - Creative Commons
8.
7 p, 439.2 KB Management of direct antiviral agent failures / Buti, Maria (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Esteban, Rafael (Esteban Mur) (Universitat Autònoma de Barcelona)
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this objective. [...]
2016 - 10.3350/cmh.2016.0107
Clinical and Molecular Hepatology, Vol. 22 (december 2016) , p. 432-438  
Registre complet - Creative Commons

Documents de recerca 3 registres trobats  
1.
222 p, 18.0 MB Cancer incidence related to pharmacological treatment of hepatitis C virus infection / Ríos Guillermo, José Pedro ; Pontes García, Caridad, dir. ; Torres Benítez, Ferran, dir. ; Valle Cano, Marta, dir.
Antecedents i objectius: La infecció crònica pel virus de l'hepatitis C (VHC) provoca cirrosi hepàtica i carcinoma hepatocel·lular (CHC). Els primers tractaments destinats a eradicar el VHC empraven interferó, sovint amb ribavirina (IFN); eren mal tolerats i reservats a pacients en bones condicions físiques. [...]
Antecedentes y objetivos: La infección crónica por el virus de la hepatitis C (VHC) provoca cirrosis hepática y carcinoma hepatocelular (CHC). Los primeros tratamientos destinados a erradicar el VHC utilizaban interferón, a menudo con ribavirina (IFN); eran mal tolerados y reservados a pacientes en buenas condiciones físicas. [...]
Background & Aims: Chronic infection by hepatitis C virus (HCV) is a well-known cause of morbi-mortality, by causing liver cirrhosis and eventually hepatocellular carcinoma (HCC). First treatments aimed to eradicate HCV were interferon (IFN) based regimes, generally associated to ribavirin; these were poorly tolerated and thus were used only in very fit patients. [...]
2022  
Registre complet - Creative Commons
2.
2 p, 9.6 MB Protein ubiquitination and its role on gene expression during the antiviral immune response / Tubau i Campuzano, Ot ; Universitat Autònoma de Barcelona. Facultat de Biociències
2022
Grau en Bioquímica [814]  
Registre complet - Creative Commons
3.
123 p, 3.1 MB Caracterización molecular del perfil de resistencias del virus de la hepatitis C después del fallo terapéutico a antivirales de acción directa mediante secuenciación masiva / Chen, Qian ; Quer, Josep, 1963-, dir. ; Perales Viejo, Celia, dir. ; Gregori i Font, Josep, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
La infección crónica por el virus de la hepatitis C constituye un problema de salud pública a nivel mundial por su contribución al desarrollo de enfermedades hepáticas avanzadas y carcinoma hepatocelular. [...]
Chronic hepatitis C infection is considered as a major public health issue worldwide due to its linkage to the development of advanced liver diseases and hepatocellular carcinoma. Currently, the availability of highly efficient and well-tolerated antiviral therapies based on combinations of direct acting antivirals (DAAs) has provided sustained virological response (SVR) in nearly 95% of patients. [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2019.  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem